Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This is an open randomized phase III study. The primary objective of this study is to compare
FEC adjuvant chemotherapy in operable breast cancer given either as fixed doses calculated
according to the patients surface area or with doses adjusted according to leukopenia after
course one in order to achieve hematological equitoxicity. The main aim of the study is to
test whether chemotherapy dosage aimed at hematological equitoxicity will improve the effect
of adjuvant chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Henrik Lindman
Collaborators:
Danish Breast Cancer Cooperative Group Danish Breast Cancer Group Pharmacia Pharmaceutical Company Scandinavian Breast Cancer Group Scandinavian Breast Group Swedish Breast Cancer Association Swedish Breast Cancer Group Swedish Cancer Foundation Swedish Cancer Society Uppsala University Oncology Department Trust